M&A Deal Summary |
|
|---|---|
| Date | 2019-09-10 |
| Target | BioVectra |
| Sector | Life Science |
| Buyer(s) | H.I.G. Private Equity |
| Sellers(s) | Questcor Pharmaceuticals |
| Deal Type | Divestiture |
| Deal Value | 250M USD |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1993 |
| PE ASSETS | 65.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
HIG Private Equity is the private equity arm of HIG Capital. The Firm focuses on management buyouts, growth equity investments, and recapitalizations of mid-sized to large companies valued between $50 million and $1 billion. HIG will also consider industry consolidations, going-privates, and corporate divestitures. Sectors of interest include aerospace, building materials, business services, consumer products, distribution, healthcare, infrastructure, contracting, manufacturing, media, oil & gas services, IT, and transportation. HIG was formed in 1993 is based in Miami, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 253 of 383 |
| Sector: Life Science M&A | 3 of 7 |
| Type: Divestiture M&A Deals | 30 of 48 |
| State: Prince Edward Island M&A | 1 of 1 |
| Country: Canada M&A | 12 of 17 |
| Year: 2019 M&A | 16 of 19 |
| Size (of disclosed) | 14 of 25 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-04 |
Nadir
São Paulo, Brazil Nadir is a glass tableware producer in Brazil and the 6th largest in the world. Nadir provides high-quality products and long-standing relationships with all major distributors and retailers. Nadir was founded in 1912 and is based in Sao Paulo, Brazil. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-24 |
RxStrategies
Boca Raton, Florida, United States RxStrategies provides the federally qualified community health centers (FQHC), other qualified entities and the pharmacy partners with a full turn-key solution for the implementation and on-going management of the 340B discount prescription drug program. RxStrategies was founded in 2003 and is based in Boca Raton, Florida. |
Sell | - |
| Category | Company |
|---|---|
| Founded | 1990 |
| Sector | Life Science |
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company that provides drugs for the treatment of autoimmune and inflammatory disorders.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Prince Edward Island M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-06-11 |
Rights to Synacthen
United States Synacthen® and Synacthen Depot® in certain countries outside the U.S. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for certain autoimmune and inflammatory conditions, but have never been developed or approved for patients in the U.S. |
Buy | $60M |
